<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39439795</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>24</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Genetic signatures of <i>AKT1</i> variants associated with worse COVID-19 outcomes - a multicentric observational study.</ArticleTitle><Pagination><StartPage>1422349</StartPage><MedlinePgn>1422349</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1422349</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2024.1422349</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">The COVID-19, triggered by the SARS-CoV-2 virus, has varied clinical manifestations, ranging from mild cases to severe forms such as fatal pneumonia and acute respiratory distress syndrome (ARDS). Disease severity is influenced by an exacerbated immune response, characterized by high pro-inflammatory cytokine levels. Inhibition of AKT can potentially suppress pathological inflammation, cytokine storm and platelet activation associated with COVID-19. In this study, we aimed to investigate the rs2494746 and rs1130214 variants in the <i>AKT1</i> gene associated with severe COVID-19 outcomes.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Peripheral blood samples and sociodemographic data from 508 individuals with COVID-19, measuring plasma cytokine concentrations using ELISA and genotyped the <i>AKT1</i> variants.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">The rs2494746-C allele was associated with severity, ICU admission, and death from COVID-19. The C allele at rs1130214 was linked to increased TNF and D-dimer levels. Moreover, both variants exhibited an increased cumulative risk of disease severity, ICU admission, and mortality caused by COVID-19. In the predictive analysis, the rs2494746 obtained an accuracy of 71%, suggesting a high probability of the test determining the severity of the disease.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="UNASSIGNED">Our findings contribute to understanding the influence of the <i>AKT1</i> gene variants on the immunological damage in individuals infected with SARS-CoV-2.</AbstractText><CopyrightInformation>Copyright © 2024 de Almeida, Tosta, Pena, Silva, Reis-Goes, Silva, Cruz, Silva, de Araújo, Rodrigues, Oliveira, Figueiredo, Vaz, Montaño-Castellón, Santana, Torres, Beltrão, Carneiro, Campos, Brites, Fortuna, Figueiredo, Trindade, Ramos and Costa.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>de Almeida</LastName><ForeName>Ingrid Marins</ForeName><Initials>IM</Initials><AffiliationInfo><Affiliation>Laboratório de Imunofarmacologia e Biologia Molecular, Instituto de Ciências da Saúde, Universidade Federal da Bahia, Salvador, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tosta</LastName><ForeName>Bruna Ramos</ForeName><Initials>BR</Initials><AffiliationInfo><Affiliation>Laboratório de Imunofarmacologia e Biologia Molecular, Instituto de Ciências da Saúde, Universidade Federal da Bahia, Salvador, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pena</LastName><ForeName>Laiane da Cruz</ForeName><Initials>LDC</Initials><AffiliationInfo><Affiliation>Laboratório de Imunofarmacologia e Biologia Molecular, Instituto de Ciências da Saúde, Universidade Federal da Bahia, Salvador, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silva</LastName><ForeName>Hatilla Dos Santos</ForeName><Initials>HDS</Initials><AffiliationInfo><Affiliation>Laboratório de Imunofarmacologia e Biologia Molecular, Instituto de Ciências da Saúde, Universidade Federal da Bahia, Salvador, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reis-Goes</LastName><ForeName>Fabiane S</ForeName><Initials>FS</Initials><AffiliationInfo><Affiliation>Laboratório de Imunologia e Biologia Molecular, Instituto de Ciências da Saúde, Universidade Federal da Bahia, Salvador, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silva</LastName><ForeName>Nívia N</ForeName><Initials>NN</Initials><AffiliationInfo><Affiliation>Laboratório de Imunologia e Biologia Molecular, Instituto de Ciências da Saúde, Universidade Federal da Bahia, Salvador, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cruz</LastName><ForeName>João Victor Andrade</ForeName><Initials>JVA</Initials><AffiliationInfo><Affiliation>Laboratório de Imunofarmacologia e Biologia Molecular, Instituto de Ciências da Saúde, Universidade Federal da Bahia, Salvador, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silva</LastName><ForeName>Mailane Dos Anjos</ForeName><Initials>MDA</Initials><AffiliationInfo><Affiliation>Laboratório de Imunofarmacologia e Biologia Molecular, Instituto de Ciências da Saúde, Universidade Federal da Bahia, Salvador, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Araújo</LastName><ForeName>Jéssica Francisco</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Laboratório de Imunofarmacologia e Biologia Molecular, Instituto de Ciências da Saúde, Universidade Federal da Bahia, Salvador, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodrigues</LastName><ForeName>Juliana Lopes</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Laboratório de Imunofarmacologia e Biologia Molecular, Instituto de Ciências da Saúde, Universidade Federal da Bahia, Salvador, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oliveira</LastName><ForeName>Gabriella</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Laboratório de Análises Clínicas, Instituto Couto Maia, Salvador, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Figueiredo</LastName><ForeName>Ricardo Gassmann</ForeName><Initials>RG</Initials><AffiliationInfo><Affiliation>Universidade Estadual de Feira de Santana, Feira de Santana, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vaz</LastName><ForeName>Sara Nunes</ForeName><Initials>SN</Initials><AffiliationInfo><Affiliation>Hospital Universitário Professor Edgard Santos, Universidade Federal da Bahia, Salvador, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montaño-Castellón</LastName><ForeName>Iris</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Hospital Universitário Professor Edgard Santos, Universidade Federal da Bahia, Salvador, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santana</LastName><ForeName>Daniele</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Hospital Universitário Professor Edgard Santos, Universidade Federal da Bahia, Salvador, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torres</LastName><ForeName>Alex</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laboratório de Imunologia e Biologia Molecular, Instituto de Ciências da Saúde, Universidade Federal da Bahia, Salvador, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beltrão</LastName><ForeName>Fabyan Esberard de Lima</ForeName><Initials>FEL</Initials><AffiliationInfo><Affiliation>Hospital Universitário Lauro Wanderley, Universidade Federal da Paraíba, João Pessoa, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carneiro</LastName><ForeName>Valdirene Leão</ForeName><Initials>VL</Initials><AffiliationInfo><Affiliation>Departamento de Ciências da Vida, Universidade do Estado da Bahia, Salvador, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Campos</LastName><ForeName>Gubio Soares</ForeName><Initials>GS</Initials><AffiliationInfo><Affiliation>Laboratório de Virologia, Instituto de Ciências da Saúde, Universidade Federal da Bahia, Salvador, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brites</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Hospital Universitário Professor Edgard Santos, Universidade Federal da Bahia, Salvador, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fortuna</LastName><ForeName>Vitor</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Laboratório de Imunologia e Biologia Molecular, Instituto de Ciências da Saúde, Universidade Federal da Bahia, Salvador, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Figueiredo</LastName><ForeName>Camila Alexandrina</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Laboratório de Imunofarmacologia e Biologia Molecular, Instituto de Ciências da Saúde, Universidade Federal da Bahia, Salvador, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trindade</LastName><ForeName>Soraya Castro</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Laboratório de Imunologia e Biologia Molecular, Instituto de Ciências da Saúde, Universidade Federal da Bahia, Salvador, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universidade Estadual de Feira de Santana, Feira de Santana, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramos</LastName><ForeName>Helton Estrela</ForeName><Initials>HE</Initials><AffiliationInfo><Affiliation>Programa de Pós-Graduação em Processos Interativos de Órgãos e Sistema, Instituto de Saúde e Ciência, Universidade Federal da Bahia, Salvador, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Costa</LastName><ForeName>Ryan Dos Santos</ForeName><Initials>RDS</Initials><AffiliationInfo><Affiliation>Laboratório de Imunofarmacologia e Biologia Molecular, Instituto de Ciências da Saúde, Universidade Federal da Bahia, Salvador, Brazil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="C494918">AKT1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C036309">fibrin fragment D</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005338">Fibrin Fibrinogen Degradation Products</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051057" MajorTopicYN="Y">Proto-Oncogene Proteins c-akt</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="Y">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005338" MajorTopicYN="N">Fibrin Fibrinogen Degradation Products</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">AKT1</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">immunogenetics</Keyword><Keyword MajorTopicYN="N">polymorphism</Keyword><Keyword MajorTopicYN="N">severity</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>23</Day><Hour>10</Hour><Minute>56</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>23</Day><Hour>10</Hour><Minute>55</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>23</Day><Hour>4</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39439795</ArticleId><ArticleId IdType="pmc">PMC11493623</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2024.1422349</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hu B, Guo H, Zhou P, Shi Z-L. Characteristics of SARS-coV-2 and COVID-19. Nat Rev Microbiol. (2021) 19:141–54. doi: 10.1038/s41579-020-00459-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-020-00459-7</ArticleId><ArticleId IdType="pmc">PMC7537588</ArticleId><ArticleId IdType="pubmed">33024307</ArticleId></ArticleIdList></Reference><Reference><Citation>Darif D, Hammi I, Kihel A, El Idrissi Saik I, Guessous F, Akarid K. The pro-inflammatory cytokines in COVID-19 pathogenesis: What goes wrong? Microb Pathog. (2021) 153:104799. doi: 10.1016/j.micpath.2021.104799</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micpath.2021.104799</ArticleId><ArticleId IdType="pmc">PMC7889464</ArticleId><ArticleId IdType="pubmed">33609650</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. . Factors associated with COVID-19-related death using OpenSAFELY. Nature. (2020) 584:430–6. doi: 10.1038/s41586-020-2521-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2521-4</ArticleId><ArticleId IdType="pmc">PMC7611074</ArticleId><ArticleId IdType="pubmed">32640463</ArticleId></ArticleIdList></Reference><Reference><Citation>Ersahin T, Tuncbag N, Cetin-Atalay R. The PI3K/AKT/mTOR interactive pathway. Mol Biosyst. (2015) 11:1946–54. doi: 10.1039/C5MB00101C</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C5MB00101C</ArticleId><ArticleId IdType="pubmed">25924008</ArticleId></ArticleIdList></Reference><Reference><Citation>Appelberg S, Gupta S, Svensson Akusjärvi S, Ambikan AT, Mikaeloff F, Saccon E, et al. . Dysregulation in Akt/mTOR/HIF-1 signaling identified by proteo-transcriptomics of SARS-CoV-2 infected cells. Emerg Microbes Infect. (2020) 9:1748–60. doi: 10.1080/22221751.2020.1799723</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2020.1799723</ArticleId><ArticleId IdType="pmc">PMC7473213</ArticleId><ArticleId IdType="pubmed">32691695</ArticleId></ArticleIdList></Reference><Reference><Citation>Pompura SL, Dominguez-Villar M. The PI3K/AKT signaling pathway in regulatory T-cell development, stability, and function. J Leukoc Biol. (2018) 103:1065–76. doi: 10.1002/JLB.2MIR0817-349R</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/JLB.2MIR0817-349R</ArticleId><ArticleId IdType="pubmed">29357116</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin S, Wu H, Wang C, Xiao Z, Xu F. Regulatory T cells and acute lung injury: cytokines, uncontrolled inflammation, and therapeutic implications. Front Immunol. (2018) 9:1545. doi: 10.3389/fimmu.2018.01545</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.01545</ArticleId><ArticleId IdType="pmc">PMC6046379</ArticleId><ArticleId IdType="pubmed">30038616</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmiedel BJ, Rocha J, Gonzalez-Colin C, Bhattacharyya S, Madrigal A, Ottensmeier CH, et al. . COVID-19 genetic risk variants are associated with expression of multiple genes in diverse immune cell types. Nat Commun. (2021) 12:6760. doi: 10.1038/s41467-021-26888-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-26888-3</ArticleId><ArticleId IdType="pmc">PMC8604964</ArticleId><ArticleId IdType="pubmed">34799557</ArticleId></ArticleIdList></Reference><Reference><Citation>Harmon BT, Devaney SA, Gordish-Dressman H, Reeves EK, Zhao P, Devaney JM, et al. . Functional characterization of a haplotype in the AKT1 gene associated with glucose homeostasis and metabolic syndrome. Hum Genet. (2010) 128:635–45. doi: 10.1007/S00439-010-0891-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S00439-010-0891-7</ArticleId><ArticleId IdType="pmc">PMC4079461</ArticleId><ArticleId IdType="pubmed">20872231</ArticleId></ArticleIdList></Reference><Reference><Citation>Masson JJR, Cherry CL, Murphy NM, Sada-Ovalle I, Hussain T, Palchaudhuri R, et al. . Polymorphism rs1385129 within glut1 gene SLC2A1 is linked to poor CD4+ T cell recovery in antiretroviral-treated HIV+ Individuals. Front Immunol. (2018) 9:900. doi: 10.3389/FIMMU.2018.00900</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/FIMMU.2018.00900</ArticleId><ArticleId IdType="pmc">PMC5966582</ArticleId><ArticleId IdType="pubmed">29867928</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin X, Xu Z, Zhang Z, Li L, Pan Q, Zheng F, et al. . Association of PI3K/AKT/mTOR pathway genetic variants with type 2 diabetes mellitus in Chinese. Diabetes Res Clin Pract. (2017) 128:127–35. doi: 10.1016/J.DIABRES.2017.04.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.DIABRES.2017.04.002</ArticleId><ArticleId IdType="pubmed">28477532</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J, Zeng Z. Combined effects of AKT serine/threonine kinase 1 polymorphisms and environment on congenital heart disease risk: A case-control study. Medicine. (2020) 99:e20400–0. doi: 10.1097/MD.0000000000020400</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000020400</ArticleId><ArticleId IdType="pmc">PMC7328912</ArticleId><ArticleId IdType="pubmed">32590727</ArticleId></ArticleIdList></Reference><Reference><Citation>Tosta BR, de Almeida IM, da Cruz Pena L, dos Santos Silva H, Reis-Goes FS, Silva NN, et al. . MTOR gene variants are associated with severe COVID-19 outcomes: A multicenter study. Int Immunopharmacol. (2023) 125:111155. doi: 10.1016/J.INTIMP.2023.111155</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.INTIMP.2023.111155</ArticleId><ArticleId IdType="pubmed">37951192</ArticleId></ArticleIdList></Reference><Reference><Citation>Penha D, Pinto EG, Matos F, Hochhegger B, Monaghan C, Taborda-Barata L, et al. . CO-RADS: coronavirus classification review. J Clin Imaging Sci. (2021) 11:9. doi: 10.25259/JCIS_192_2020</Citation><ArticleIdList><ArticleId IdType="doi">10.25259/JCIS_192_2020</ArticleId><ArticleId IdType="pmc">PMC7981938</ArticleId><ArticleId IdType="pubmed">33767901</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan F, Ye T, Sun P, Gui S, Liang B, Li L, et al. . Time course of lung changes on chest CT during recovery from 2019 novel coronavirus (COVID-19) pneumonia. Radiology. (2020) 295:715–21. doi: 10.1148/RADIOL.2020200370</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/RADIOL.2020200370</ArticleId><ArticleId IdType="pmc">PMC7233367</ArticleId><ArticleId IdType="pubmed">32053470</ArticleId></ArticleIdList></Reference><Reference><Citation>Groß R, Kleger A. COVID-19 and diabetes — where are we now? Nat Metab. (2022) 4:1611–3. doi: 10.1038/s42255-022-00691-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42255-022-00691-w</ArticleId><ArticleId IdType="pubmed">36369292</ArticleId></ArticleIdList></Reference><Reference><Citation>Ssentongo P, Zhang Y, Witmer L, Chinchilli VM, Ba DM. Association of COVID-19 with diabetes: a systematic review and meta-analysis. Sci Rep. (2022) 12:1–8. doi: 10.1038/s41598-022-24185-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-24185-7</ArticleId><ArticleId IdType="pmc">PMC9684130</ArticleId><ArticleId IdType="pubmed">36418912</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu H, He Y, Yang X, Liang L, Zhan Z, Ye Y, et al. . Anti-malarial agent artesunate inhibits TNF-α-induced production of proinflammatory cytokines via inhibition of NF-κB and PI3 kinase/Akt signal pathway in human rheumatoid arthritis fibroblast-like synoviocytes. Rheumatology. (2007) 46:920–6. doi: 10.1093/RHEUMATOLOGY/KEM014</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/RHEUMATOLOGY/KEM014</ArticleId><ArticleId IdType="pubmed">17314215</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaz de Paula CB, Nagashima S, Liberalesso V, Collete M, da Silva FPG, Oricil AGG, et al. . COVID-19: immunohistochemical analysis of TGF-β Signaling pathways in pulmonary fibrosis. Int J Mol Sci. (2021) 23:168. doi: 10.3390/IJMS23010168/S1</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/IJMS23010168/S1</ArticleId><ArticleId IdType="pmc">PMC8745764</ArticleId><ArticleId IdType="pubmed">35008594</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin JO, Yu Q. Fucoidan delays apoptosis and induces pro-inflammatory cytokine production in human neutrophils. Int J Biol Macromol. (2015) 73:65–71. doi: 10.1016/J.IJBIOMAC.2014.10.059</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.IJBIOMAC.2014.10.059</ArticleId><ArticleId IdType="pubmed">25445688</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S, Yu NK, Kaang BK. CTCF as a multifunctional protein in genome regulation and gene expression. Exp Mol Med. (2015) 47:e166–6. doi: 10.1038/emm.2015.33</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emm.2015.33</ArticleId><ArticleId IdType="pmc">PMC4491725</ArticleId><ArticleId IdType="pubmed">26045254</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y, Xu X, Zhao W, Zhang Y, Chen K, Li Y, et al. . RAD21 is the core subunit of the cohesin complex involved in directing genome organization. Genome Biol. (2023) 24:255. doi: 10.1186/S13059-023-02982-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/S13059-023-02982-1</ArticleId><ArticleId IdType="pmc">PMC10303866</ArticleId><ArticleId IdType="pubmed">37381036</ArticleId></ArticleIdList></Reference><Reference><Citation>Varikasuvu SR, Varshney S, Dutt N, Munikumar M, Asfahan S, Kulkarni PP, et al. . D-dimer, disease severity, and deaths (3D-study) in patients with COVID-19: a systematic review and meta-analysis of 100 studies. Sci Rep. (2021) 11:1–11. doi: 10.1038/s41598-021-01462-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-01462-5</ArticleId><ArticleId IdType="pmc">PMC8576016</ArticleId><ArticleId IdType="pubmed">34750495</ArticleId></ArticleIdList></Reference><Reference><Citation>Pelzl L, Singh A, Funk J, Witzemann A, Marini I, Zlamal J, et al. . Antibody-mediated procoagulant platelet formation in COVID-19 is AKT dependent. J Thromb Haemostasis. (2022) 20:387. doi: 10.1111/JTH.15587</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/JTH.15587</ArticleId><ArticleId IdType="pmc">PMC8646637</ArticleId><ArticleId IdType="pubmed">34752677</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Valle DM, Kim-Schulze S, Huang HH, Beckmann ND, Nirenberg S, Wang B, et al. . An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med 2020 26:10. (2020) 26:1636–43. doi: 10.1038/s41591-020-1051-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-1051-9</ArticleId><ArticleId IdType="pmc">PMC7869028</ArticleId><ArticleId IdType="pubmed">32839624</ArticleId></ArticleIdList></Reference><Reference><Citation>Hufnagel K, Fathi A, Stroh N, Klein M, Skwirblies F, Girgis R, et al. . Discovery and systematic assessment of early biomarkers that predict progression to severe COVID-19 disease. Commun Med. (2023) 3:1–13. doi: 10.1038/s43856-023-00283-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s43856-023-00283-z</ArticleId><ArticleId IdType="pmc">PMC10089829</ArticleId><ArticleId IdType="pubmed">37041310</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorog DA, Storey RF, Gurbel PA, Tantry US, Berger JS, Chan MY, et al. . Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium. Nat Rev Cardiol. (2022) 19:475–95. doi: 10.1038/s41569-021-00665-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41569-021-00665-7</ArticleId><ArticleId IdType="pmc">PMC8757397</ArticleId><ArticleId IdType="pubmed">35027697</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>